Immune activation in first-in-human anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) phase I/II MATINS trial: Part I dose-escalation, safety, and efficacy results.

Petri Bono,Reetta Virtakoivu,Felix Vaura,Panu Jaakkola,Shishir Shetty,Alain Thibault,Maja J.A. de Jonge,Anna Minchom,Yuk Ting Ma,Christina Yap,Debbie Robbrecht,Annika Pasanen,Tanja Skyttä,Romillie Cruz,Markku Jalkanen,Sirpa Jalkanen,Jami Mandelin,Matti K. Karvonen,Jussi Koivunen,Maija Hollmén

Immune activation in first-in-human anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) phase I/II MATINS trial: Part I dose-escalation, safety, and efficacy results.

2020

3097Background: The scavenger receptor CLEVER-1 mediates the clearance of “unwanted” self-components and is highly expressed on tumor associated macrophages (TAMs). CLEVER-1 expression is associate...

Keywords:

Immunology
Monoclonal antibody
first in human
dose escalation
immune activation
Pathology
Medicine
Macrophage antibody
phase i ii

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations